Lauren Sciences LLC, a private biotechnology company in New York, N.Y., recently received a third grant from The ALS Association to support the continued development of LAUR-301, Lauren Sciences’ novel V-Smart Nanomedicine designed specifically for ALS.

V-Smart Nanomedicines encapsulate and deliver non-brain penetrant therapeutic agents across the blood-brain barrier (BBB), a barrier that protects the brain, and into the central nervous system (CNS) after non-invasive administration. LAUR-301 is engineered to target and selectively release at degenerating motor neurons (nerve cells) in ALS.

Lauren Sciences hopes LAUR-301 becomes an approved, effective new treatment for ALS that protects against neurodegeneration and induces neuro-restoration, thus, slowing down or reversing the disease.

To read the news announcement from Lauren Sciences, click here.